Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2008

01.01.2008 | Preclinical Study

Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumors

verfasst von: Rachel E. Ellsworth, Jeffrey A. Hooke, Brad Love, Jennifer L. Kane, Heather L. Patney, Darrell L. Ellsworth, Craig D. Shriver

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Pathological grade is a useful prognostic factor for stratifying breast cancer patients into favorable (well-differentiated tumors) and less favorable (poorly-differentiated tumors) outcome groups. The current system of tumor grading, however, is subjective and a large proportion of tumors are characterized as intermediate-grade tumors, making determination of optimal treatments difficult. To determine whether molecular profiles can discriminate breast disease by grade, patterns and levels of allelic imbalance (AI) at 26 chromosomal regions frequently altered in breast disease were examined in 185 laser microdissected specimens representing well-differentiated (grade 1; n = 55), moderately-differentiated (grade 2; n = 71), and poorly-differentiated (grade 3; n = 59) stage I–IV breast tumors. Overall levels of AI were significantly higher in grade 3 compared to grade 1 tumors (P < 0.05). Grades 1 and 3 showed distinct genetic profiles - grade 1 tumors were associated with large deletions of chromosome 16q22, while alterations at 9p21, 11q23, 13q14, 17p13.1 and 17q12 were characteristics of grade 3 carcinomas. In general, levels and patterns of AI in grade 2 carcinomas were intermediate between grade 1 and grade 3 tumors. Patterns of AI accurately categorized ∼70% of samples into high- or low-grade disease groups, suggesting that the majority of breast tumors have genetic profiles consistent with high- or low-grade, and that molecular signatures of breast tumors can be useful for more accurate characterization of invasive breast cancer.
Literatur
1.
Zurück zum Zitat Millis RR et al (1998) Tumor grade does not change between primary and recurrent mammary carcinoma. Eur J Cancer 34:548–553PubMedCrossRef Millis RR et al (1998) Tumor grade does not change between primary and recurrent mammary carcinoma. Eur J Cancer 34:548–553PubMedCrossRef
2.
Zurück zum Zitat Roylance R et al (2002) Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. J Pathol 196:32–36PubMedCrossRef Roylance R et al (2002) Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. J Pathol 196:32–36PubMedCrossRef
3.
Zurück zum Zitat Roylance R et al (1999) Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59:1433–1436PubMed Roylance R et al (1999) Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59:1433–1436PubMed
4.
Zurück zum Zitat Buerger H et al (2001) Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 194(2):165–170PubMedCrossRef Buerger H et al (2001) Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 194(2):165–170PubMedCrossRef
5.
Zurück zum Zitat Sotiriou C et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262–272PubMedCrossRef Sotiriou C et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262–272PubMedCrossRef
6.
Zurück zum Zitat Henson DE et al (1991) Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer 68(10):2142–2149PubMedCrossRef Henson DE et al (1991) Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer 68(10):2142–2149PubMedCrossRef
7.
Zurück zum Zitat Elston CW, Ellis IO (1998) Systemic pathology 3E. In: Elston CW, Ellis IO (eds) The breast. Churchill Livingstone, Edinburgh pp. 3–10 Elston CW, Ellis IO (1998) Systemic pathology 3E. In: Elston CW, Ellis IO (eds) The breast. Churchill Livingstone, Edinburgh pp. 3–10
8.
Zurück zum Zitat American Joint Committee on Cancer. 2002. AJCC Cancer Staging Manual. 6 ed. Greene FL et al (eds). New York: Springer American Joint Committee on Cancer. 2002. AJCC Cancer Staging Manual. 6 ed. Greene FL et al (eds). New York: Springer
9.
Zurück zum Zitat Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359–377PubMed Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359–377PubMed
10.
Zurück zum Zitat Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 19:403–410PubMedCrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 19:403–410PubMedCrossRef
11.
Zurück zum Zitat Ellsworth DL et al (2003a) Laser capture microdissection of paraffin-embedded tissues. Biotechniques 34(1):42–46 Ellsworth DL et al (2003a) Laser capture microdissection of paraffin-embedded tissues. Biotechniques 34(1):42–46
12.
Zurück zum Zitat Ellsworth RE et al (2003b) High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomarkers Prev 12(9):915–919 Ellsworth RE et al (2003b) High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomarkers Prev 12(9):915–919
13.
Zurück zum Zitat Medintz IL et al (2000) Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis. Genome Res 10:1211–1218PubMedCrossRef Medintz IL et al (2000) Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis. Genome Res 10:1211–1218PubMedCrossRef
14.
Zurück zum Zitat Ellsworth RE et al (2005) Allelic imbalance in primary breast carcinomas and metastatic tumors of the axillary lymph nodes. Mol Cancer Res 3:71–77PubMedCrossRef Ellsworth RE et al (2005) Allelic imbalance in primary breast carcinomas and metastatic tumors of the axillary lymph nodes. Mol Cancer Res 3:71–77PubMedCrossRef
15.
Zurück zum Zitat Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767PubMedCrossRef Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767PubMedCrossRef
16.
Zurück zum Zitat Cleton-Jansen AM et al (2004) Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer 41:109–116PubMedCrossRef Cleton-Jansen AM et al (2004) Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer 41:109–116PubMedCrossRef
17.
Zurück zum Zitat Bieche I, Lidreau R (2000) Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol Carcinog 29(3):151–158PubMedCrossRef Bieche I, Lidreau R (2000) Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol Carcinog 29(3):151–158PubMedCrossRef
18.
Zurück zum Zitat Lukas J et al (1995) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503–506PubMedCrossRef Lukas J et al (1995) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503–506PubMedCrossRef
19.
Zurück zum Zitat Seitz S et al (2001) Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J Pathol 194:318–326PubMedCrossRef Seitz S et al (2001) Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J Pathol 194:318–326PubMedCrossRef
20.
Zurück zum Zitat Winqvist R et al (1995) Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 55(12):2660–2664PubMed Winqvist R et al (1995) Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 55(12):2660–2664PubMed
Metadaten
Titel
Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumors
verfasst von
Rachel E. Ellsworth
Jeffrey A. Hooke
Brad Love
Jennifer L. Kane
Heather L. Patney
Darrell L. Ellsworth
Craig D. Shriver
Publikationsdatum
01.01.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9547-2

Weitere Artikel der Ausgabe 2/2008

Breast Cancer Research and Treatment 2/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.